Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebselen - Sound Pharmaceuticals

Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: DR-3305; Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 13 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Medical University of South Carolina; Nattermann; Sound Pharmaceuticals; University of Oxford
  • Class Anti-ischaemics; Antiasthmatics; Antibacterials; Antiulcers; Antivirals; Azoles; Benzene derivatives; Ketones; Mood stabilisers; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules; Vascular disorder therapies; Vestibular disorder therapies
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Meniere's disease
  • Phase II Bipolar disorders; COVID 2019 infections; Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Phase I Depressive disorders
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 14 Jun 2021 Phase-II clinical trials in severe COVID-2019 infections in USA (PO) (NCT04483973)
  • 14 Jun 2021 Phase-II clinical trials in moderate COVID-2019 infections in USA (PO) (NCT04484025)
  • 05 May 2021 Phase-III clinical trials in Meniere's disease in USA (PO) (Sound Pharmaceuticals pipeline, May 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top